PEG-modified/site-mutated IL-2 SHR-1916

{
  "id": "MLC-T-ONC-015913",
  "term": "PEG-modified/site-mutated IL-2 SHR-1916",
  "field": "Oncology and biomedicine",
  "definition": "A polyethylene glycol (PEG)-modified and site-mutated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, PEG-modified/site-mutated IL-2 SHR-1916 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the selective proliferation of CD8+ T cells and natural killer (NK) cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.",
  "synonyms": [
    "PEG-modified/site-mutated interleukin-2 SHR-1916",
    "IL-2 derivative SHR-1916"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/peg-modified-site-mutated-il-2-shr-1916/"
}